---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059498"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:03:54.244975+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Korro Bio appoints Dr. Kemi Olugemo as Chief Medical Officer

## Summary
- Dr. Olugemo joined as CMO effective May 13, 2024; prior role was VP of Global Clinical Development at Ultragenyx.
- Previously Head of Clinical Development at Laronde (now Sail Bio) and Executive Director at Ionis Pharmaceuticals.
- Over 10 years of neurology and rare disease clinical development experience, including global approvals.
- M.D. from University of Maryland School of Medicine with fellowship in Neuroimmunology & Multiple Sclerosis.

## SEC filing metadata
- accession: 0000950170-24-059498
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017024059498/0000950170-24-059498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017024059498/krro-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059498
- JSON: https://secwatch.observer/filing/0000950170-24-059498.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.